drug
PRV-131
Phase 1updated 3mo agoby Privo Technologies Inc
Phase 1community read0 votes
🐶 often sniffed alongside
top 7- drugcisplatin3 co-mentions · 3 sources
- drugPRV-2113 co-mentions · 3 sources
- drugcisplatin SR3 co-mentions · 3 sources
- drugiCIP3 co-mentions · 3 sources
- tagOncology2 co-mentions · 1 sources
- companyVirginia Commonwealth University1 co-mentions · 1 sources
- companyNational Cheng-Kung University Hospital1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying PRV-131
- phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- phase3A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- phase3Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase2A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- phase1A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- phase3A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
News(2)
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 3mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 3mo ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that